Qifeng Wang
Impact in
- Cancer Research top 1%
- MicroRNA in disease regulation
- Cancer-related molecular mechanisms research
- Cancer, Hypoxia, and Metabolism
- Molecular Biology top 5%
- Circular RNAs in diseases
- RNA modifications and cancer
Papers in
-
- Gastric Cancer Management and Outcomes 44
- Lung Cancer Diagnosis and Treatment 31
- Lung Cancer Treatments and Mutations 18
- Oncology 60
- Cancer Immunotherapy and Biomarkers 13
Qifeng Wang
153 papers receiving 3.1k citations
Peers
Comparison fields: 5 of 133
- Cancer Research 1.5k
- Molecular Biology 1.7k
- Oncology 687
- Pulmonary and Respiratory Medicine 646
- Surgery 619
Countries citing papers authored by Qifeng Wang
This map shows the geographic impact of Qifeng Wang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Qifeng Wang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Qifeng Wang more than expected).
Fields of papers citing papers by Qifeng Wang
This network shows the impact of papers produced by Qifeng Wang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Qifeng Wang. The network helps show where Qifeng Wang may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Qifeng Wang, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 1 | |
| 2 | 2024 | 5 | |
| 3 | 2024 | 0 | |
| 4 | 2024 | 1 | |
| 5 | 2024 | 0 | |
| 6 | 2024 | 4 | |
| 7 | 2023 | 2 | |
| 8 | First-Line Anlotinib Combined with Stereotactic Body Radiation Therapy for an Octogenarian with Pulmonary Carcinosarcoma | 2022 | 1 |
| 9 | 2022 | 8 | |
| 10 | 2021 | 5 | |
| 11 | 2020 | 21 | |
| 12 | 2020 | 69 | |
| 13 | 2020 | 17 | |
| 14 | 2019 | 8 | |
| 15 | 2017 | 29 | |
| 16 | 2016 | 1 | |
| 17 | 2015 | 1 | |
| 18 | 2014 | 19 | |
| 19 | 2011 | 230 | |
| 20 | 2011 | 114 |
About Qifeng Wang
Qifeng Wang is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Surgery, Cancer Research and Otorhinolaryngology, having authored 165 papers that have together received 3.1k indexed citations. Recurring topics across this work include Esophageal Cancer Research and Treatment (69 papers), Gastric Cancer Management and Outcomes (44 papers), Lung Cancer Diagnosis and Treatment (31 papers), Esophageal and GI Pathology (22 papers), Lung Cancer Treatments and Mutations (18 papers), RNA modifications and cancer (15 papers), Cancer Immunotherapy and Biomarkers (13 papers) and MicroRNA in disease regulation (13 papers). The work is most often cited by research in Cancer Research (1.5k citations), Molecular Biology (1.7k citations), Oncology (687 citations), Pulmonary and Respiratory Medicine (646 citations) and Surgery (619 citations). Qifeng Wang has collaborated with scholars based in China, United States and United Kingdom. Frequent co-authors include Xianghuo He, Shenglin Huang, Linhui Liang, Ming Yao, Jinjun Li, Taoyang Chen, Xiang Du, Yingjun Zhao, Weiqi Sheng and Weijie Guo. Their work appears in journals such as Frontiers in Oncology, BMC Cancer, Radiation Oncology, Cancer Medicine and Annals of Surgical Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.